



Project Name WEST POINT POLYSACCHARIDE BULK DRUG SUBSTANCE BLDG 63 E
Industry Code 13 Pharmaceutical & Biotech **Project Type** Plant Expansion
TIV (USD) 45,000,000
SIC Code 2836 Biological Products, Except Diagnostic Substances **Sector** Ingredients (APIs, Bulk, Excipients, etc.)
SIC Product 2836*0032 Active Pharmaceutical Ingredients (APIs)
Status Active **Last Update** 04-Feb-2022 **Initial Release** 09-Sep-2021
Environmental Air (A) Land (L) Water (W) **Construction Labor Preference** Unconfirmed
Operations Labor Preference Union

[PEC Activity Diagram](#)



Square Footage Existing Sq. Ft. 6,100,000 Sq. Ft.

Plant Owner Merck and Company Incorporated **Plant Parent** Merck & Company Incorporated
Plant Name West Point Sterile Injectables & Oral Solutions Vaccines **Unit Name**
Plant ID 1512949
Location 770 Sumneytown Pike **Phone** +1 215 652 5000
City/State West Point, Pennsylvania 19486 U.S.A. **Zone/County** PA*06, Montgomery

Project Responsibility Project Company

Project Contact

<p>Project Manager Merck and Company Incorporated 770 Sumneytown Pike West Point, Pennsylvania 19486 U.S.A.</p>	<p>Douglas Chubb Director of Engineering [Tel.] +1 215 652 5000 [E-Mail] douglas_chubb@merck.com ; [LinkedIn] douglas-chubb-pe</p>
<p>C/M Integrated Project Services Incorporated 721 Arbor Way Suite 100 Blue Bell, Pennsylvania 19422 U.S.A.</p>	<p>Mark Bechta Purchasing Manager [Tel.] +1 610 828 4090 [E-Mail] mbechta@ipsdb.com</p>
<p>C/M Integrated Project Services Incorporated 721 Arbor Way Suite 100 Blue Bell, Pennsylvania 19422 U.S.A.</p>	<p>Richard Sanderson Construction Manager [Tel.] +1 610 828 4090 [E-Mail] rsanderson@ipsdb.com</p>
<p>G/C Delran Builders Company Incorporated 7909 Flourtown Avenue Wyndmoor, Pennsylvania 19038 U.S.A.</p>	<p>Gary Brown Project Manager [Tel.] +1 215 836 1213 [E-Mail] gbrown@delranbuilders.com ; [LinkedIn] gary-brown-9949129</p>

PEC® Timing P2

PEC® Activity Owner Review of Issue

Project Probability Medium (70-80%)

Scope Merck and Company Incorporated with Integrated Project Services (IPS) and Delran Builders performs Owner Review of Issue for West Point Polysaccharide Bulk Drug Substance Building 63 Expansion Phase 2. DETAILS: Within 400-acre campus, expand "Building 63", by approximately 60,000 sqft for the production of pneumococcal conjugate vaccine polysaccharides. REQUIRES INSTALLATION/TIE-INS OF: Building Management Systems (BMS), Temperature and Humidity Controls, Voice/Data/Wireless System, Air/Gas Vacuum System, Media and Inoculum Preparation Equipment, Fermentation Equipment, Centrifuges, Single-Use Secondary Clarification Equipment, Bioburden Reduction Equipment/Hydrophilic Filtration Equipment, Conjugation Equipment, Ultrafiltration/Diafiltration (UH/DF) Equipment, Tangential Flow Filtration Equipment, Cleanrooms (Class 100-10,000/ISO 5-7), Tanks, Flowmeters, Water-For-Injection System (WFI), Single-Use Ion-Exchange Chromatography Columns, Carbon Filtration Equipment, Single-Use Mixing Equipment, Clean Steam Supply, Multi-Step Precipitation Equipment (Ethanol/Propanol/Sodium Acetate), Refrigeration, Freezers, pH Meters, Checkweighers, Hygienic Piping, Controls (PLC/DCS), Aseptic Fill/Finish Equipment, Sampling Systems, Bar Coding/Scanning/Labeling Equipment, Conveyors (Belt), Emergency Generator, Electrical Distribution, Central Utility Tie-Ins, Uninterrupted Power Supply, Pumps, Motors, Valves. ENVIRONMENTAL: (A) HEPA Filtration System, Dust Collectors; (L) Containment; (W) Pre-Wastewater Treatment System Tie-Ins

Schedule Merck and Company Incorporated with Integrated Project Services (IPS) and Delran Builders continues with Owner Review of Issue through 2Q22 (Apr). Project team releases any remaining Equipment RFQs plus Subcontractor Bid Documents 2Q22 (May-Jun). Tentative Construction Kick-Off 3Q22 (Jul). Project Completion 3Q24 (Sep). **NOTE: Must be pre-qualified to be a vendor at Merck. If not yet approved, contact Wayne Farmer for qualification information.**

Details Feb-2022 Project in Owner Review of Issue.

Project Milestones	AFE 202204	Sub Bid Doc 202205	Completion 30-Sep-2024	Precision QUARTER
	Equip RFQ 202205	Kick-Off 202207	Kickoff Slippage 3 Months	Duration 27 Months
Engineering Contracting	Electrical	Environmental HVAC	Instrumentation Mechanical	
Project Key Needs		Control Room	Process Equip Heat Transfer	
Instrumentation	Electrical	Mechanical HVAC	Storage	
Piping/Fittings	Insulation/Coatings	Environmental Utilities	Valves	
Communications		Batch Process	Packaging	

Material Handling

Matter Phase	Liquid	Solid
Energy		
Buy		
Sell		

Plant Standard Contacts

Functional/Actual Title	Contact Name/E-mail	Telephone/On-site	QC Date/LinkedIn ID
Plant Manager	Claudio Campanella	[Phn.] +1 215 652 5000	Feb-2022
Associate Director	claudio_campanella@merck.com	Yes	claudio-campanella-43836924
Maintenance Manager	William Egan	[Phn.] +1 215 652 7265	Feb-2022
Associate Director, Equipment Development & Maintenance	bill.egan@merck.com	Yes	william-egan-79416711
Purchasing Manager	Wayne Farmer	[Phn.] +1 732 594 0891	Feb-2022
Senior Site Contract Administrator		Yes	wayne-farmer-345a854
Engineering Manager	Douglas Chubb	[Phn.] +1 215 652 5000	Feb-2022
Director of Engineering	douglas_chubb@merck.com	Yes	douglas-chubb-pe
Environmental Manager	Amy Earley	[Phn.] +1 215 652 4247	Feb-2022
Sr. Environmental Engineer	amy.earley@merck.com	Yes	amy-earley-17085925
Safety Manager	Amy Earley	[Phn.] +1 215 652 4247	Feb-2022
Sr. Environmental Engineer	amy.earley@merck.com	Yes	amy-earley-17085925
Utilities Manager	Paul Andrel	[Phn.] +1 215 652 5000	Feb-2022
Lead Maintenance & Utilities Supervisor	paul.andrel@merck.com	Yes	
Human Resource Manager	Patrick Dunn	[Phn.] +1 215 652 5000	Feb-2022
AVP, HR Operations	patrick_dunn@merck.com	Yes	

Historical Reports

Project Name	Report Date	TIV	Phase
WEST POINT POLYSACCHARIDE BULK DRUG SUBSTANCE BLDG 63 EXPANSION PHASE 2	09-Sep-2021	45,000,000 USD	Project Justification (P1 - 16)
WEST POINT POLYSACCHARIDE BULK DRUG SUBSTANCE BLDG 63 EXPANSION PHASE 2	18-Nov-2021	45,000,000 USD	Project Justification (P1 - 16)
WEST POINT POLYSACCHARIDE BULK DRUG SUBSTANCE BLDG 63 EXPANSION PHASE 2	04-Feb-2022	45,000,000 USD	Owner Review of Issue (P2 - 19)